

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

3

Application Number	10/777,792
Filing Date	February 11, 2004
First Named Inventor	Schenk, Dale B.
Art Unit	1649
Examiner Name	Daniel E. Kolker
Attorney Docket Number	15270J-004766US

ENCLOSURES (Check all that apply)

- | | | |
|--|---|---|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input type="checkbox"/> Information Disclosure Statement

<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input checked="" type="checkbox"/> Power of Attorney (1 page)
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____
<input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Statement under 37 CFR 3.73(b) (1 page)
Publication Review from PAIR dated 6/25/2008 (1 page) |
|--|---|---|

Remarks The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

It appears that the Power of Attorney and Statement under 37 CFR 3.73(b) filed on October 30, 2007, were not considered as evidenced by the attached PAIR Publication Review dated 6/25/2008. The Power of Attorney and Statement under 27 CFR 3.73(b) are resubmitted herewith.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Townsend and Townsend and Crew LLP		
Signature	<i>Rosemarie L. Celli</i>		
Printed name	Rosemarie L. Celli		
Date	June 25, 2008	Reg. No.	42,397

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being filed via EFS-Web with the United States Patent and Trademark Office on the date shown below.

Signature	<i>Rosemarie L. Celli</i>		
Typed or printed name	Rosemarie L. Celli	Date	June 25, 2008

10/777,792 Prevention and treatment of amyloidogenic disease

**06-25-
2008::16:04:17**

Publication Review

PATENT APPLICATION Number: 10/777,792

Projected Publication Date:

U.S. Filing or 371(c) Date: 02-11-2004

PCT Filed: -

PCT Number: -

Title of Invention: Prevention and treatment of amyloidogenic disease

Inventor Name(s): Dale Schenk , Burlingame, CA

Correspondence Name and Address: TOWNSEND AND TOWNSEND AND CREW, LLP,
TWO EMBARCADERO CENTER,EIGHTH FLOOR
SAN FRANCISCO CA 94111-3834

Assignee Name and Address: Neuralab Ltd,Neuralab Ltd, ,, ,,

Applicant Selected Figure Published:

Other Publications of this Application: US 2005-0059802 A1 03-17-2005

Parent Continuity Data: This application is a Continuation of 09/723,544 filed on Nov.28,
2000
is a continuation of 09/580,018 filed on May.26, 2000

Foreign Application Priority Data:

Close Window